Clinical Cancer Research · 2004 · 358 citations · 27 references
Life SciencesMolecular BiologyOncologyChemotherapyDna RepairGene ExpressionCancer TranscriptomicsMolecular Tumor ProfilingExcision Repair Cross-complementation Group 1Kaplan-meier Confidence IntervalsMessenger Rna Expression SignaturesNon-small Cell Lung Cancer TherapyReal-time Polymerase Chain Reaction (Pcr)Reverse Transcription Polymerase Chain Reaction (Rt-pcr)
PURPOSE: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. EXPERIMENTAL DESIGN: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcitabine/cisplatin/vinorelbine versus gemcitabine/vinorelbine followed by vinorelbine/ifosfamide. We analyzed RRM1 and ERCC1 mRNA expression in paraffin-embedded samples obtained from bronchoscopy by real-time quantitative reverse transcription-PCR. Results were correlated with survival using the Kaplan-Meier method. RESULTS: A total of 100 patients were assessed. There was a strong correlation between RRM1 and ERCC1 mRNA expression levels (Spearman r = 0.410; P < 0.001). In the gemcitabine/cisplatin arm, patients with low RRM1 mRNA expression levels had significantly longer median survival than those with high levels [13.7 versus 3.6 months; 95% confidence interval (CI), 9.6-17.8 months; P = 0.009]. Median survival was also significantly longer among patients with low mRNA expression levels of both RRM1 and ERCC1 (not reached), than among those with high levels of both genes (6.8 months; 95% CI, 2.6-11.1 months; P = 0.016). CONCLUSIONS: RRM1 mRNA expression is a crucial predictive marker of survival in gemcitabine/cisplatin-treated patients. Genetic testing of RRM1 mRNA expression levels can and should be used to personalize chemotherapy.
27
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations
Medicine, Oncology, Pharmacology +11
Frank V. Fossella, Jose R. Pereira, Joachim von Pawel et al. · Journal of Clinical Oncology · 2003 · 943 citations
Medicine, Oncology, Pharmacology +15